A recent Medscape article contained good news for the 1.3 billion people affected by migraines worldwide; the FDA just approved the first intravenous drug to prevent them. Lundbeck’s Vyepti is a humanized monoclonal antibody that is taken once every 3 months in either 100 or 300 mg doses. Its approval was based on the results of two Phase III clinical studies that focused on both episodic and chronic migraines. Lundbeck expects the drug to be available in early April.
Quick Hits: FDA Clears New Migraine Prevention Drug
The intravenous medication is taken every 3 months to prevent migraines.
Feb 26, 2020
Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!Take Quiz
Discover Our Content Hub
Access Healthcare Packaging's free educational content library!Unlock Learning Here